

# SYED OMAR ALI, MD

---

## LANGUAGES

English and Spanish: Native

## EDUCATION

1995 – 1999 Medical: University of Chicago, Pritzker School of Medicine, Chicago, IL, M.D.

1991 – 1995 Undergraduate: United States Military Academy, West Point, NY, B.S. in Life Sciences

---

## POSTGRADUATE TRAINING

2002 – 2005 Residency Dermatology, San Antonio Uniformed Services Health Education Consortium, JBSA Fort Sam Houston, TX

1999 – 2000 Internship Pediatrics, San Antonio Uniformed Services Health Education Consortium, JBSA Fort Sam Houston, TX

## MEDICAL LICENSURE

Licensure: State of Texas  
License Number: N9338

Licensure: State of California  
License Number: C197728

**BOARD CERTIFICATION** American Board of Dermatology

## PROFESSIONAL EXPERIENCE

2025 – Present Dermatologist, Skin and Beauty Center – West Hills, CA

2016 – 2025 Dermatologist, CEO, Acclaim Dermatology PLLC, Sugar Land, TX

2013 – 2018	Chief Medical Officer, Soivelle Skincare, LLC
2012 – 2015	Dermatologist, Suzanne Bruce and Associates, Houston, TX
2011 – 2012	Locums Staff Dermatologist, Coastal Dermatology, Savannah, GA
2009 – 2012	Locums Staff Dermatologist, Newnan Dermatology, Newnan, GA
2008 – 2012	President, Aliderm LLC
2005 – 2012	Locums Staff Dermatologist, Georgia Dermatology and Skin Cancer Center, LLC. Dublin, GA
2008	Chief, Phipps TMC-Balad, Iraq
2005 – 2012 Center, Fort Gordon, GA	Chief, Dermatology Service, D.D. Eisenhower Army Medical
2005 – 2012	Teledermatologist, US Army Medical Corps
2001 – 2002	OIC, TMC, Camp Edwards, Camp Edwards, Republic of Korea
2000 – 2001	OIC, Aviation Medicine, TMC-McWethy, Fort Sam Houston, TX

## **PROFESSIONAL MEMBERSHIPS**

2010 – 2011	Vice President, Association of Military Dermatologists
2002 – Present	Fellow, American Academy of Dermatology
2002 – 2012	American Society for Dermatologic Surgery
2012 – 2023	Houston Dermatology Society

## **TEACHING APPOINTMENTS**

2006 – 2012	Clinical Assistant Professor, Department of Medicine and Dermatology, Medical College of Georgia, Augusta, GA
2006 – 2012	Clinical Assistant Professor, Department of Family Practice, Medical College of Georgia, Augusta, GA

## **LABORATORY RESEARCH ACTIVITIES**

1992	Armed Forces Institute of Pathology, Department of Forensic Toxicology, Walter Reed Army Medical Center, Washington, D.C.
------	---

## **PUBLICATIONS**

**Ali SO**, Tocci GP. Recurrent Lesion on the Right Ala Nasi and an Odontogenic Cyst in a Soldier. 2011 July; 51-53.

**Ali SO**, Rivera JM. Gottron's Papules and Dermatomyositis. Journal of Dermatology for Physician Assistants. 2008 Spring;2(2):26. Trowbridge DB, **Ali SO**, Waibel KH. Atypical Tuberculin Skin Test Responses. Consultant for Pediatricians. 2007 Aug; 861.

**Ali SO**, Vogel PS. Surgical Pearl: Simple Method for Controlling Surgical Sharps. J Am Acad Dermatol. 2006 May;54(5):878-9.

**Ali, SO**, McCarthy RD, Davis BM. Case reports: Cutaneous Small Vessel Vasculitis Due to Famciclovir Therapy. J Drugs Dermatol. 2005 Jul-Aug;4(4):486-9.

**Ali, SO**, Pak HS. Self-Assessment Examination of the American Academy of Dermatology: A Localized Granulomatous Eruption. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):549-551.

**Ali SO**, Davis BM. Cutaneous Small Vessel Vasculitis Resulting from Famciclovir Therapy. Gross and Microscopic Dermatology Symposium for the 63rd Annual Meeting of the American Academy of Dermatology. February 2005.

**Ali SO**. Secondary Syphilis. Clinical Pathological Case presentation. 28th Annual Uniformed Services Dermatology Seminar, 2004.

**Ali SO**, Pak HS, Gardner TL. Sarcoidosis During Treatment with Pegylated Interferon-Alpha and Ribavirin for Chronic Hepatitis C. Gross and Microscopic Dermatology Symposium for the 62nd Annual Meeting of the American Academy of Dermatology. February 2004.

**Ali SO**, Warschaw KE. Chapter 30 Mycobacterial Infections, Dermatology Secrets, 2000. **Ali SO**, Warschaw KE. Chapter 32 Deep Fungal Infections, Dermatology Secrets, 2000. **Ali SO**, Sartori C. Parvovirus B19, Pediatric News SAMC, 2000.

## **CLINICAL RESEARCH EXPERIENCE**

1. Safety and Efficacy of Escalating Doses of a Topical Once Daily for Two or Three Consecutive Days when Used on Full Face, Full Balding Scalp or Approximately 250 CM<sup>2</sup> on the Chest in Subjects with Actinic Keratosis. Part 2: A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, 8-Week Trial. Sub-Investigator. 2013.
2. A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of a Topical in Subjects with Plaque Psoriasis. Sub- Investigator. 2013.
3. A Phase 2b, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Efficacy, Safety, Local Tolerability and Pharmacokinetics of 2 Dose Strengths and 2 Regimens of an Ointment in Subjects with Chronic Plaque Psoriasis. Sub-Investigator. 2013.

4. A Randomized, Parallel, Open Label, Multi-Center Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with a Spray Versus a Lotion in Subjects with Moderate to Severe Plaque Psoriasis. Sub-Investigator. 2013.
5. A Multi-Center, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of a Foam Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis. Sub-Investigator. 2013.
6. A Safety and Efficacy Study to Compare a Gel with Vehicle Control in Patients with Acne Vulgaris. Principal Investigator. 2014.
7. A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of a Topical in Subjects with Plaque Psoriasis. Principal Investigator. 2014.
8. A Randomized, Parallel, Open Label, Multi-Center Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with a Spray Versus a Lotion in Subjects with Moderate to Severe Plaque Psoriasis. Principal Investigator. 2014.
9. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses Administered by Intravenous Infusion to Patients with Moderate to Severe Chronic Plaque Psoriasis. Sub-Investigator. 2014.
10. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Antibiotic Compared to Placebo in the Treatment of Acne Vulgaris. Sub-Investigator. 2014.
11. A Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Phase II Dose-Ranging Study to Evaluate the Efficacy and Safety of a Gel in Patients with Actinic Keratosis (AK) on the Head (Face and/ or Scalp). Sub-Investigator. 2014.
12. A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multi-Center Study Comparing a Generic Cream to Reference Listed Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis. Sub-Investigator. 2014.
13. An Open-Label, Multi-Center, 52-Week, Long-Term Study to Evaluate the Safety and Efficacy of a Topical in Subjects with Plaque Psoriasis. Sub-Investigator. 2014.
14. A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare a Topical Gel to a Topical Gel, and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis on the Trunk and Extremities. Principal Investigator. 2015.
15. A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Bioequivalence of a Generic Cream and Reference Listed Cream and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis. Principal Investigator. 2015.
16. A Multi-Center Open-Label Evaluation of the Safety of Tablets in the Treatment of Acne

Vulgaris. Sub-Investigator. 2015.

17. A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study of a Topical Gel in Subjects with Acne Vulgaris. Sub-Investigator. 2015.
18. An Open-Label (Part A) and a Double-Blind, Randomized, Placebo-Controlled (Part B) Study, with an Open-Label Extension, of a Cream Applied Topically to Subjects with Alopecia Areata. Sub-Investigator. 2015.
19. Efficacy and Safety of a Topical in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-Month Follow-Up. Sub-Investigator. 2015.
20. A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of an Injectable Product for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects. Sub-Investigator. 2015.
21. A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of an Injectable Product. Sub-Investigator. 2015.
22. Questionnaire Study (Hyperhidrosis). Sub-Investigator. 2015.
23. A Phase I Methodology Study to Investigate Use of a Clinical Assay for Assessing Cutaneous Injection for Induced Anhidrosis on the Back. Sub-Investigator. 2015.
24. A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multi-Center Study Comparing an Ointment to a Reference Listed Drug in the Treatment of Plaque Psoriasis. Sub-investigator. 2015.
25. A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of a Lotion in the Treatment of Plaque Psoriasis. Sub-investigator. 2015.
26. A Phase III, Multi-Center, Placebo Controlled Study to Investigate Efficacy and Safety of an Injection for Lipodystrophy. Principal Investigator. 2018.
27. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Atopic Dermatitis. Principal Investigator. 2018
28. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in a Topical Medication for Acne. Principal Investigator. 2018
29. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Psoriasis. Principal Investigator. 2019
30. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Injectable Medication for Atopic Dermatitis. Principal Investigator. 2019
31. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Injectable Medication for Psoriasis. Principal Investigator. 2019

32. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Psoriasis. Principal Investigator. 2020
33. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Atopic Dermatitis. Principal Investigator. 2020
34. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Injectable Medication for Psoriasis. Principal Investigator. 2021
35. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Infusion Medication for Psoriasis. Principal Investigator. 2022
36. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in a Topical Medication for Atopic Dermatitis. Principal Investigator. 2022
37. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Atopic Dermatitis. Principal Investigator. 2022
38. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in a predictive device for Injectable Medication for Psoriasis. Principal Investigator. 2023
39. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Psoriasis. Principal Investigator. 2023
40. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy and Safety in an Oral Medication for Atopic Dermatitis. Principal Investigator. 2024
41. A Phase III, Multi-Center, Placebo Controlled Study to Evaluate Efficacy in a Topical Medication for Androgenetic Alopecia. Principal Investigator. 2025